Bioconjunction Services

Bioconjugation Services

Our Single-Source Solution™ is designed to support the entire life cycle of bioconjugates from development through cGMP manufacture.

Whether your conjugate is a chelating agent for diagnostics or therapeutic radioisotope labeling, an adjuvant like aluminum hydroxide, an antibody-drug conjugate, or another antibody, GBI can develop and manufacture them at cGMP-compliant scales for clinical applications (and commercial launches beginning in 2023).

GBI’s Bioconjugation Experience


Our experience in the field includes:

  • Coupling small-molecule cancer drugs to antibodies
  • Conjugating various molecules to carrier proteins (such as KLH and CRM 197) as immunogens for antibody generation
  • Opioid conjugate vaccines
  • Conjugating two antibodies, both full-length and fragments
  • Cleavable and non-cleavable linkers
  • Conjugating genomic DNA to antibodies
  • Coupling metal chelates onto recombinant proteins and antibodies (including difficult IgMs) for radiolabeling
  • Adsorption of aluminum hydroxide gels onto antibodies
  • Biotinylation of proteins for use with streptavidin- or avidin-based reagents
  • Enzyme labeled antibodies for signal generation in diagnostic applications
  • Conjugating fluorescent dyes to antibodies
  • Developing key properties of therapeutic proteins in the optimization of in vitro and in vivo performance

Because of our extensive background in bioconjugation, our development team has a full, in-depth understanding of the issues that accompany these processes such as incorporation levels, active site masking, and isotope uptake and stability.

Our Schedule II Capabilities

In 2018 GBI was awarded a Schedule II manufacturer license from the Drug Enforcement Agency to handle controlled substances. We have used these controlled substances to successfully develop and manufacture protein conjugate vaccines for opioid addiction.

Learn More
Sally A. Quataert, Ph. D., Chief Executive Officer,
Quotation mark_A

We have selected GBI based on the years of experience they have in bioconjugation and in developing and manufacturing cADCs, radioimmunoconjugates, and other conjugates. They demonstrated a great deal of flexibility, worked within our budget, and delivered our ADC ahead of schedule.

Quotation mark_B
Sally A. Quataert, Ph.D., RQAP-GLP Chief Executive Officer, For-Robin, Inc.

Contact Us About Your CDMO Project

Learn More